Iowa State researchers develop technology for early detection of viruses

October 30, 2007

AMES, Iowa -- Iowa State University researchers have developed a technology that detects a single molecule of the virus associated with cervical cancer in women.

That's a significant improvement over the current test for the human papillomavirus, said Edward Yeung, an Iowa State Distinguished Professor and the Robert Allen Wright Chair in Chemistry who led the research team that developed the new test. The current test, the Nobel Prize-winning polymerase chain reaction technique, requires 10 to 50 virus molecules for detection.

"We are always interested in detecting smaller and smaller amounts of material at lower and lower concentrations," Yeung said. "Detecting lower levels means earlier diagnosis."

The discovery by Yeung, who's also a senior chemist and deputy program director for the U.S. Department of Energy's Ames Laboratory at Iowa State; Jiangwei Li, an Iowa State doctoral student; and Ji-Young Lee, a former Iowa State doctoral student; will be published in the Nov. 1 issue of the journal Analytical Chemistry.

Their work was funded by a five-year, $950,000 grant from the National Institutes of Health with additional support from The Robert Allen Wright Endowment for Excellence at Iowa State.

The project advanced just as human papillomavirus made national headlines. In June of 2006, the U.S. Food and Drug Administration approved a vaccine developed to prevent cervical cancer, precancerous lesions and genital warts caused by four types of the virus. The vaccine has been approved for females ages 9 to 26.

The Centers for Disease Control and Prevention reports the human papillomavirus is the most common sexually transmitted infection in the U.S. The agency estimates about 6.2 million Americans are infected every year and over half of all sexually active Americans are infected at some time in their lives.

Yeung said single molecule detection of the virus could help women and families decide to get vaccinated. He said vaccines administered after such early detection could still have time to stop the virus.

The new detection technology improves current technology by eliminating a step to amplify DNA samples for testing. Although the current test is efficient and well understood, the amplification can cause small contaminants to create test errors.

Yeung's single molecule spectroscopy technique involves creating chemical reagents that recognize and fluorescently tag the genetic sequence of the human papillomavirus. Test samples pass through a laser beam that lights the tags. Cameras capture the images for computer analysis.

The research team tested the technique using samples from normal Pap smears. They also spiked some of those samples with the virus to make sure the tests picked up known amounts of the virus.

Although this test concentrated on detecting the human papillomavirus, Yeung said it should detect HIV, avian flu and other viruses as well.

Will the technology make it to medical labs?

Yeung -- who helped start CombiSep Inc. in 1999 to develop and market chemical separation instruments for pharmaceutical and life sciences research (the company merged with Advanced Analytical Technologies Inc. of Ames late last year) -- said he won't be directly involved in taking the detection technology to market. But he said companies have expressed some interest in licensing and developing the technology.

As that project moves on, Yeung will continue looking for ways to detect chemical targets at the smallest limits. He said the next challenge is to figure out how to detect single molecules of proteins.
-end-
Contacts:

Edward Yeung, Chemistry, (515) 294-8062, yeung@ameslab.gov

Mike Krapfl, News Service, (515) 294-4917, mkrapfl@iastate.edu

Iowa State University

Related Cervical Cancer Articles from Brightsurf:

HPV strains may impact cervical cancer prognosis
An analysis of cervical cancers in Ugandan women has uncovered significant genomic differences between tumours caused by different strains of human papillomavirus (HPV), signifying HPV type may impact cervical cancer characteristics and prognosis.

American Cancer Society updates guideline for cervical cancer screening
An updated cervical cancer screening guideline from the American Cancer Society reflects the rapidly changing landscape of cervical cancer prevention in the United States, calling for less and more simplified screening.

Disasters can affect cervical cancer screening for years
Screening is important for the early detection of cervical cancer, but rates were significantly affected, in some areas for years, following a devastating earthquake and tsunami in Japan.

Cervical cancer elimination possible within two decades in the US
At current levels of screening and HPV vaccination, cervical cancer incidence in the US is projected to fall below the threshold of elimination by 2038-2046.

Cervical cancer screening saves lives
Three-year interval in screening for cervical cancer is as effective as annual checkups, study finds.

Cervical cancer could be eliminated within a century
Cervical cancer could be eliminated worldwide as a public health issue within the next century.

25 years of learning to combat cervical cancer
A recent paper from the lab of Professor Sudhir Krishna at the National Centre for Biological Sciences, Bangalore, reviews the progress made in cervical cancer research over the past 25 years.

Cervical cancer screening numbers drop off in women 45-65
Virtually all cervical cancers are caused by HPV, and much of the attention in recent years has focused on preventing infections in younger women through HPV vaccination.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cost-effectiveness analysis of 12 cervical cancer screenings
This cost-effectiveness analysis incorporates women's preferences and estimates quality of life and economic outcomes for 12 cervical cancer screening strategies.

Read More: Cervical Cancer News and Cervical Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.